Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Related Information
Registry Information

Alternate Title

Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients with Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Basic Trial Information

Special Category: NCI Web site featured trial

Objectives

Primary

1. To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy comprising carboplatin and paclitaxel with or without bevacizumab increases the duration of overall survival of patients with recurrent platinum-sensitive ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer.
2. To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in these patients.

Secondary

1. To determine if the addition of bevacizumab to the second-line and maintenance phase of treatment increases the duration of progression-free survival relative to second-line paclitaxel and carboplatin alone in these patients.
2. To prospectively determine the incidence of carboplatin and paclitaxel hypersensitivity in these patients undergoing retreatment with both agents as first recurrence therapy.
3. To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases quality of life (QOL) of patients with recurrent platinum-sensitive ovarian epithelial cancer or primary peritoneal cavity cancer, as measured by the FACT-O trial outcome index and Rand SF-36 physical functioning scale.
4. To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases QOL relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum-sensitive ovarian epithelial cancer or primary peritoneal cavity cancer.

Entry Criteria

Disease Characteristics:

• Patients must have histologic diagnosis of ovarian epithelial carcinoma, primary peritoneal cavity carcinoma, or fallopian tube carcinoma
  • Recurrent disease*
    • Patients whom have already undergone secondary cytoreduction for recurrent disease are excluded

   [Note: *Patients with biochemical recurrence, by definition, are not eligible for surgical randomization and should be considered for the chemotherapy randomization alone. (This eligibility criterion does not apply to patients enrolled after August 7, 2011)]

• The following histologic epithelial cell types** are allowed:
  • Serous adenocarcinoma
  • Endometrioid adenocarcinoma
  • Mucinous adenocarcinoma
  • Undifferentiated carcinoma
  • Clear cell adenocarcinoma
  • Mixed epithelial carcinoma
  • Transitional cell carcinoma
  • Malignant Brenner Tumor
  • Adenocarcinoma not otherwise specified

   [Note: **Prior histologic diagnosis of borderline, low malignant potential (grade 0) epithelial carcinoma that was surgically resected and subsequently developed an unrelated, new invasive ovarian epithelial or primary peritoneal cavity cancer allowed provided the histological criteria for epithelial cell type is met]

• Patients with synchronous primary endometrial cancer or a past history of primary endometrial cancer are excluded, unless all of the following conditions are met:
  • Stage not greater than I-B
  • No more than superficial myometrial invasion
  • No vascular or lymphatic invasion
  • No poorly differentiated subtypes, including papillary serous, clear cell or other FIGO grade 3 lesions

• Patients must have had a complete response to front-line platinum-taxane therapy (at least 3 cycles) and a treatment-free interval without clinical evidence of progressive disease lasting at least 6 months
  • Front-line therapy may have included a biologic agent (e.g., bevacizumab) but an interval of at least 6 months must have elapsed after completion of therapy
  • A complete response to front-line chemotherapy must include the following:
    • Negative physical exam
    • Negative pelvic exam
    • Normalization of CA125, if elevated at baseline
    • Negative radiographic assessment of disease
  • Front-line treatment may include maintenance therapy following complete clinical or pathological response provided recurrent disease is not identified earlier than 6 months following completion of all anticancer treatment
    • Patients receiving maintenance biological therapy or hormonal therapy are eligible provided their recurrence is documented more than 6 months from primary cytotoxic chemotherapy completion (includes maintenance chemotherapy) AND a minimum of 4 weeks has elapsed since their last infusion of biological therapy
    • Patients enrolled on GOG-0198 or patients receiving hormonal therapy for biochemical or non-measurable recurrence disease are eligible provided their recurrence is documented more than 6 months following the completion of primary cytotoxic chemotherapy AND a minimum of 4 weeks must have elapsed since their last exposure to hormonal therapy (This eligibility criterion does not apply to patients enrolled after August 7, 2011)

• Clinically evident measurable or nonmeasurable disease*** defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded)
  • Each lesion must be ≥ 20 mm when measured by conventional techniques, MRI or CT scan, or ≥ 10 mm when measured by spiral CT scan
  • Nonmeasurable disease defined by symptomatic ascites or pleural effusion***
  • Patients with clinically evident measurable or nonmeasurable disease*** must also have any 1 of the following:
    • CA-125 > 2 times upper limit of normal
    • Histologic confirmation of recurrence in the absence of an elevated CA-125 and measurable disease

   [Note: ***Patients with nonmeasurable, clinically evident disease, by definition, are not eligible for surgical randomization and should be considered for the chemotherapy randomization alone. Only measurable disease is permitted as of 8-7-2011.]

• Patients enrolled after August 7, 2011 must be candidates for cytoreductive surgery and consent to have their surgical treatment determined by randomization

Prior/Concurrent Therapy:

• See Disease Characteristics
• No more than 1 prior regimen of chemotherapy (maintenance therapy is not considered a second regimen)
• No prior radiotherapy to any portion of the abdominal cavity or pelvis
• No prior chemotherapy for any other abdominal or pelvic tumor other than ovarian, fallopian tube, or primary peritoneal cancer
• No major surgical procedure, open biopsy, or dental extractions or other dental surgery/procedure that results in an open wound within the past 28 days
• No placement of vascular access device or core biopsy within the past 7 days
• No concurrent immunotherapy or radiotherapy
• No anticipation of need for major surgical procedure during the course of the study

Patient Characteristics:

Inclusion criteria:

• GOG performance status of 0, 1, or 2
• Platelet count ≥ 100,000/mm³
• Absolute neutrophil count ≥ 1,500/mm³
• Creatinine (non-IDMS) ≤ 1.5 times upper limit of normal (ULN)
• Total bilirubin ≤ 1.5 times ULN
• SGOT/AST and alkaline phosphatase ≤ 2.5 times ULN (< 5.0 times ULN in the presence of liver metastasis)
• Urine protein-to-creatinine ratio < 1.0 mg/dL
• Signed an approved informed consent and authorization permitting release of personal health information
• Patients with allergic (i.e., hypersensitivity) reactions to these chemotherapeutic agents are eligible if they were successfully retreated following a desensitization program or protocol

Exclusion criteria:

• Patients who require parenteral hydration or nutrition and have evidence of partial bowel obstruction or perforation
• Patients with uncontrolled infection
• Patients with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
• Patients with peripheral neuropathy ≥ grade 2
• Patients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds
• Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
• Patients of childbearing potential not practicing adequate contraception or patients who are pregnant or nursing
• Patients with other invasive malignancies, with the exception of nonmelanoma skin cancer, or patients who had (or have) any evidence of the other cancer present within the past 5 years or whose previous cancer treatment contraindicates this protocol therapy
• Patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major vessels
• Patients with a history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or a history of stroke within the past 5 years
• Patients with clinically significant cardiovascular disease including any of the following:
  • Significant cardiac conduction abnormalities (e.g., PR interval > 0.24 sec or 2nd or 3rd degree atrioventricular block)
  • Uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg
  • Myocardial infarction, cardiac arrhythmia, or unstable angina within the past 6 months
  • New York Heart Association grade II or greater congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • Grade II or greater peripheral vascular disease except episodes of ischemia < 24 hrs in duration that are managed non-surgically and without permanent deficit
  • History of cerebrovascular accident within the past 6 months
  • No significant traumatic injury within the past 28 days

Expected Enrollment

Outcomes

Overall survival

Progression-free survival
Frequency and severity of adverse events

Outline

This is a multicenter study. Patients are assigned to 1 of 2 treatment groups. Patients who are not candidates for surgical cytoreduction (i.e., those for whom complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking) are eligible to receive chemotherapy after randomization (does not apply to patients enrolled onto the study after August 7, 2011). Patients who are eligible for surgery undergo abdominal exploration with cytoreduction and undergo tumor tissue collection and complete a quality-of-life questionnaire before and after surgery. All patients are then randomized to 1 of 2 treatment arms.

• Arm I: Patients receive paclitaxel IV over 3 hours or docetaxel IV over 1 hour and carboplatin over 30 minutes on day 1.

• Arm II: Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1.

Treatment in both arms repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients with measurable disease achieving a clinical response (CR) receive 6-8 courses of therapy. Patients with stable disease or partial regression receive a maximum of 6 courses. Patients without measurable lesions as determined by a CT scan prior to initiating study treatment continue therapy for 6 courses or, if CA-125 normalizes, for 2 cycles beyond CA-125 normalization, whichever is greater. Patients in arm II then receive a maintenance regimen comprising bevacizumab IV over 30-90 minutes. Treatment with bevacizumab alone repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 10 years.

Trial Contact Information

Trial Lead Organizations

Gynecologic Oncology Group

Robert Coleman, MD, Protocol chair		Ph: 713-745-3357; 800-392-1611 Email: rcoleman@mdanderson.org
Scott Eisenkop, MD, FACOG, Protocol co-chair		Ph: 408-378-6131
Deborah Armstrong, MD, Protocol co-chair		Ph: 410-614-2743 Email: darmstro@jhmi.edu
Thomas Herzog, MD, Protocol co-chair		Ph: 212-305-3410 Email: th2135@columbia.edu
Paul Sabbatini, MD, Protocol co-chair		Ph: 212-639-6423; 800-525-2225

U.S.A.
Alaska
	Anchorage
	Providence Cancer Center
		Clinical Trials Office - Providence Cancer Center	Ph:  907-261-3109
California
	Long Beach
	Todd Cancer Institute at Long Beach Memorial Medical Center
		Robert Bristow	Ph:  562-933-0900
	Los Angeles
	Jonsson Comprehensive Cancer Center at UCLA
		Clinical Trials Office - Jonsson Comprehensive Cancer Center at UCLA	Ph:  888-798-0719
	Kaiser Permanente Medical Center - Los Angeles
		Scott Lentz, MD	Ph:  323-783-4018
	Mountain View
	Palo Alto Medical Foundation
		Albert Pisani	Ph:  650-934-7000
	San Francisco
	UCSF Helen Diller Family Comprehensive Cancer Center
		Clinical Trials Office - UCSF Helen Diller Family Comprehensive Cancer Center	Ph:  877-827-3222
	Stanford
	Stanford Cancer Center
		Clinical Trials Office - Stanford Cancer Center	Ph:  650-498-7061
			Email: cctoffice@stanford.edu
Colorado
	Aurora
	Aurora Presbyterian Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	University of Colorado Cancer Center at UC Health Sciences Center
		Clinical Trials Office - University of Colorado Cancer Center	Ph:  720-848-0650
	Boulder
	Boulder Community Hospital
		Clinical Trials Office - Boulder Community Hospital	Ph:  303-938-5253
	Colorado Springs
	Penrose Cancer Center at Penrose Hospital
		Clinical Trials Office - Penrose Cancer Center	Ph:  719-776-5275
	Denver
	CCOP - Colorado Cancer Research Program
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Porter Adventist Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Presbyterian - St. Luke's Medical Center
		Clinical Trials Office - Presbyterian - St. Luke's Medical Center	Ph:  303-839-6000
	Rose Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	St. Anthony Central Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	St. Joseph Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Englewood
	Rocky Mountain Gynecologic Oncology
		Kevin Davis, MD	Ph:  303-781-9090
	Swedish Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Grand Junction
	St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Greeley
	North Colorado Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Littleton
	Littleton Adventist Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Lone Tree
	Sky Ridge Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Longmont
	Hope Cancer Care Center at Longmont United Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Loveland
	McKee Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Parker
	Parker Adventist Hospital
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Pueblo
	St. Mary - Corwin Regional Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Thornton
	North Suburban Medical Center
		Eduardo Pajon, MD	Ph:  303-399-8020ext2261
	Wheat Ridge
	Exempla Lutheran Medical Center
		Clinical Trials Office - Exempla Lutheran Medical Center	Ph:  303-403-3605
Connecticut
	Hartford
	Helen and Harry Gray Cancer Center at Hartford Hospital
		Clinical Trials Office - Helen and Harry Gray Cancer Center	Ph:  860-545-5363
	Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
		Philip Stella, MD	Ph:  734-712-1000
	New Britain
	George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
		Clinical Trials Office - George Bray Cancer Center	Ph:  860-224-5660
Delaware
	Lewes
	Tunnell Cancer Center at Beebe Medical Center
		Clinical Trials Office - Tunnell Cancer Center	Ph:  302-645-3171
	Newark
	CCOP - Christiana Care Health Services
		Clinical Trial Office - CCOP - Christiana Care Health Services	Ph:  302-623-4450
Florida
	Fort Myers
	Florida Gynecologic Oncology - Fort Myers
		Edward Grendys, MD	Ph:  239-992-0077
	Saint Petersburg
	Women's Cancer Associates
		James LaPolla, MD	Ph:  727-821-9688
Georgia
	Augusta
	MBCCOP - Medical College of Georgia Cancer Center
		Sharad Ghamande, MD	Ph:  706-721-3992
	Columbus
	John B. Amos Cancer Center
		Clinical Trials Office - John B. Amos Cancer Center	Ph:  706-660-6404
	Gainesville
	Northeast Georgia Medical Center
		Andrew Green	Ph:  770-535-3553
	Savannah
	Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
		Clinical Trials Office - Curtis and Elizabeth Anderson Cancer Institute	Ph:  912-350-8568
Idaho
	Boise
	Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
		Clinical Trials Office - Saint Alphonsus Cancer Care Center	Ph:  208-367-7954
Illinois
	Chicago
	Robert H. Lurie Comprehensive Cancer Center at Northwestern University
		Clinical Trials Office - Robert H. Lurie Comprehensive Cancer Center at Northwestern University	Ph:  312-695-1301
			Email: cancer@northwestern.edu
	Rush University Medical Center
		Clinical Trials Office - Rush University Medical Center	Ph:  312-942-5498
			Email: clinical_trials@rush.edu
	University of Chicago Cancer Research Center
		Clinical Trials Office - University of Chicago Cancer Research Center	Ph:  773-834-7424
	Hinsdale
	Gynecologic Oncology
		Sudarshan Sharma, MD	Ph:  630-856-6757
	Springfield
	Regional Cancer Center at Memorial Medical Center
		Clinical Trials Office - Regional Cancer Center at Memorial Medical Center	Ph:  217-788-4233
	Urbana
	CCOP - Carle Cancer Center
		Clinical Trials Office - CCOP - Carle Cancer Center	Ph:  800-446-5532
Indiana
	Elkhart
	Elkhart Clinic, LLC
		Michael Rodriguez	Ph:  574-296-3200
	Elkhart General Hospital
		Michael Rodriguez	Ph:  574-294-2621
	Michiana Hematology-Oncology, PC - Elkhart
		Michael Rodriguez	Ph:  574-389-0414
	Indianapolis
	Indiana University Melvin and Bren Simon Cancer Center
		Clinical Trials Office - Indiana University Cancer Center	Ph:  317-274-2552
	St. Vincent Oncology Center
		Gregory Sutton, MD	Ph:  317-415-6740
	Kokomo
	Howard Community Hospital
		Michael Rodriguez	Ph:  765-453-8571
	La Porte
	Center for Cancer Therapy at LaPorte Hospital and Health Services
		Michael Rodriguez	Ph:  219-326-2683
	Mishawaka
	Michiana Hematology-Oncology, PC - South Bend
		Michael Rodriguez	Ph:  574-234-5123
	Saint Joseph Regional Medical Center
		Michael Rodriguez	Ph:  574-237-7111
	Munster
	Community Hospital
		Mohamad Kassar	Ph:  219-836-4503
	Plymouth
	Michiana Hematology Oncology PC - Plymouth
		Michael Rodriguez	Ph:  574-936-2585
	South Bend
	CCOP - Northern Indiana CR Consortium
		Michael Rodriguez	Ph:  574-647-7370 800-284-7370
	Memorial Hospital of South Bend
		Clinical Trials Office - Memorial Hospital of South Bend	Ph:  800-284-7370
	Michiana Hematology-Oncology, PC - South Bend
		Michael Rodriguez	Ph:  574-234-5123
	Westville
	Michiana Hematology Oncology PC - La Porte
		Michael Rodriguez	Ph:  219-324-1790
Iowa
	Des Moines
	CCOP - Iowa Oncology Research Association
		Robert Behrens	Ph:  515-244-7586 888-244-6061
	John Stoddard Cancer Center at Iowa Lutheran Hospital
		Clinical Trials Office - John Stoddard Cancer Center at Iowa Lutheran Hospital	Ph:  515-241-8704
	John Stoddard Cancer Center at Iowa Methodist Medical Center
		Clinical Trials Office - John Stoddard Cancer Center at Iowa Methodist Medical Center	Ph:  515-241-6727
	Medical Oncology and Hematology Associates at John Stoddard Cancer Center
		Robert Behrens	Ph:  515-282-2921
	Medical Oncology and Hematology Associates at Mercy Cancer Center
		Robert Behrens	Ph:  515-643-8740
	Mercy Cancer Center at Mercy Medical Center - Des Moines
		Robert Behrens	Ph:  515-643-8206 888-221-4849
	Iowa City
	Holden Comprehensive Cancer Center at University of Iowa
		Cancer Information Service	Ph:  800-237-1225
Kansas
	Chanute
	Cancer Center of Kansas, PA - Chanute
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Dodge City
	Cancer Center of Kansas, PA - Dodge City
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	El Dorado
	Cancer Center of Kansas, PA - El Dorado
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Fort Scott
	Cancer Center of Kansas - Fort Scott
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Independence
	Cancer Center of Kansas-Independence
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Kingman
	Cancer Center of Kansas, PA - Kingman
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Liberal
	Cancer Center of Kansas, PA - Liberal
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Newton
	Cancer Center of Kansas, PA - Newton
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Overland Park
	Saint Luke's Hospital - South
		Rakesh Gaur, MD	Ph:  913-948-5588
	Parsons
	Cancer Center of Kansas, PA - Parsons
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Prairie Village
	CCOP - Kansas City
		Rakesh Gaur, MD	Ph:  913-948-5588
	Pratt
	Cancer Center of Kansas, PA - Pratt
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Salina
	Cancer Center of Kansas, PA - Salina
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Wellington
	Cancer Center of Kansas, PA - Wellington
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Wichita
	Associates in Womens Health, PA - North Review
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Cancer Center of Kansas, PA - Wichita
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Cancer Center of Kansas, PA - Medical Arts Tower
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	CCOP - Wichita
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Via Christi Cancer Center at Via Christi Regional Medical Center
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
	Winfield
	Cancer Center of Kansas, PA - Winfield
		Shaker Dakhil, MD, FACP	Ph:  316-262-4467
Louisiana
	Baton Rouge
	Woman's Hospital
		Giles Fort, MD	Ph:  225-358-1071
Maryland
	Baltimore
	Greater Baltimore Medical Center Cancer Center
		Clinical Trials Office - Greater Baltimore Medical Center Cancer Center	Ph:  443-849-3706
	Elkton MD
	Union Hospital of Cecil County
		Mark Borowsky	Ph:  410-398-4000
Massachusetts
	Worcester
	UMASS Memorial Cancer Center - University Campus
		Susan Zweizig, MD	Ph:  508-334-1160
Michigan
	Ann Arbor
	CCOP - Michigan Cancer Research Consortium
		Philip Stella, MD	Ph:  734-712-1000
	Saint Joseph Mercy Cancer Center
		Philip Stella, MD	Ph:  734-712-1000
	University of Michigan Comprehensive Cancer Center
		Clinical Trials Office - University of Michigan Comprehensive Cancer Center	Ph:  800-865-1125
	Battle Creek
	Battle Creek Health System Cancer Care Center
		Gilbert Padula	Ph:  616-966-8000
	Big Rapids
	Mecosta County Medical Center
		Gilbert Padula	Ph:  231-796-8691
	Dearborn
	Oakwood Cancer Center at Oakwood Hospital and Medical Center
		Clinical Trials Office - Oakwood Cancer Center at Oakwood Hospital and Medical Center	Ph:  313-593-8090
	Detroit
	Barbara Ann Karmanos Cancer Institute
		Clinical Trials Office - Barbara Ann Karmanos Cancer Institute	Ph:  313-576-9363
	Josephine Ford Cancer Center at Henry Ford Hospital
		Thomas Buekers	Ph:  313-916-1850 888-734-5322
	Flint
	Hurley Medical Center
		Clinical Trials Office - Hurley Medical Center	Ph:  810-762-8057
	Grand Rapids
	Butterworth Hospital at Spectrum Health
		Gilbert Padula	Ph:  616-391-2799
	CCOP - Grand Rapids
		Gilbert Padula	Ph:  616-391-1230
	Gynecologic Oncology of West Michigan
		Gordon Downey, MD	Ph:  616-957-3398
	Lacks Cancer Center at Saint Mary's Health Care
		Gilbert Padula	Ph:  616-752-5222
	Grosse Pointe Woods
	Van Elslander Cancer Center at St. John Hospital and Medical Center
		Clincial Trials Office - Van Elslander Cancer Center at St. John Hospital and Medical Center	Ph:  313-343-3166
	Jackson
	Foote Memorial Hospital
		Philip Stella, MD	Ph:  734-712-1000
	Kalamazoo
	Borgess Medical Center
		Raymond Lord, MD	Ph:  269-373-7458
	Bronson Methodist Hospital
		Raymond Lord, MD	Ph:  269-373-7458
	West Michigan Cancer Center
		Clinical Trials Office - West Michigan Cancer Center	Ph:  269-373-7458
	Lansing
	Sparrow Regional Cancer Center
		Clinical Trials Office - Sparrow Regional Cancer Center	Ph:  517-364-2890
	Livonia
	St. Mary Mercy Hospital
		Philip Stella, MD	Ph:  734-712-1000
	Muskegon
	Mercy General Health Partners
		Gilbert Padula	Ph:  231-672-2000
	Pontiac
	St. Joseph Mercy Oakland
		Philip Stella, MD	Ph:  734-712-1000
	Port Huron
	Mercy Regional Cancer Center at Mercy Hospital
		Philip Stella, MD	Ph:  734-712-1000
	Reed City
	Spectrum Health Reed City Hospital
		Gilbert Padula	Ph:  231-832-3271
	Royal Oak
	William Beaumont Hospital - Royal Oak Campus
		Clinical Trials Office - William Beaumont Hospital - Royal Oak Campus	Ph:  248-551-7695
	Saginaw
	Seton Cancer Institute at Saint Mary's - Saginaw
		Clinical Trials Office - Seton Cancer Institute - Saginaw	Ph:  989-776-8411
	Saint Joseph
	Lakeside Cancer Specialists, PLLC
		Michael Rodriguez	Ph:  269-428-4411
	St. Joseph
	Lakeland Regional Cancer Care Center - St. Joseph
		Michael Rodriguez	Ph:  269-983-8698 800-303-8399
	Traverse City
	Munson Medical Center
		Gilbert Padula	Ph:  231-935-6202
	Warren
	St. John Macomb Hospital
		Philip Stella, MD	Ph:  734-712-1000
Minnesota
	Burnsville
	Fairview Ridges Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Coon Rapids
	Mercy and Unity Cancer Center at Mercy Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Duluth
	St. Luke's Hospital Cancer Care Center
		Tanya Repka, MD, FACP	Ph:  218-726-3081
	Edina
	Fairview Southdale Hospital
		Clinical Trials Office - Fairview Southdale Hospital	Ph:  612-625-3650
	Fridley
	Mercy and Unity Cancer Center at Unity Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Hutchinson
	Hutchinson Area Health Care
		Patrick Flynn, MD	Ph:  612-863-8585
	Maplewood
	HealthEast Cancer Care at St. John's Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Minnesota Oncology - Maplewood
		Patrick Flynn, MD	Ph:  612-863-8585
	Minneapolis
	Hennepin County Medical Center - Minneapolis
		Clinical Trials Office - Hennepin County Medical Center - Minneapolis	Ph:  612-873-5911
	Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
		Clinical Trials Office - Virginia Piper Cancer Institute	Ph:  612-863-5654
	New Ulm
	New Ulm Medical Center
		Patrick Flynn, MD	Ph:  612-863-8585
	Robbinsdale
	Humphrey Cancer Center at North Memorial Outpatient Center
		Clinical Trials Office - Humphrey Cancer Center at North Memorial Outpatient Center	Ph:  763-520-1893
	Saint Louis Park
	CCOP - Metro-Minnesota
		Patrick Flynn, MD	Ph:  612-863-8585
	Park Nicollet Cancer Center
		Patrick Flynn, MD	Ph:  612-863-8585
	Saint Paul
	United Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Shakopee
	St. Francis Cancer Center at St. Francis Medical Center
		Patrick Flynn, MD	Ph:  612-863-8585
	St. Paul
	Regions Hospital Cancer Care Center
		Clinical Trials Office - Regions Hospital Cancer Care Center	Ph:  651-254-1517
	Stillwater
	Lakeview Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Waconia
	Ridgeview Medical Center
		Patrick Flynn, MD	Ph:  612-863-8585
	Willmar
	Willmar Cancer Center at Rice Memorial Hospital
		Patrick Flynn, MD	Ph:  612-863-8585
	Woodbury
	Minnesota Oncology - Woodbury
		Patrick Flynn, MD	Ph:  612-863-8585
Mississippi
	Jackson
	St. Dominic Cancer Center
		Donald Seago	Ph:  601-200-3070
	University of Mississippi Cancer Clinic
		James Thigpen, MD	Ph:  601-984-5590
Missouri
	Columbia
	Ellis Fischel Cancer Center at University of Missouri - Columbia
		Clinical Trial Office - Ellis Fischel Cancer Center	Ph:  573-882-7440
	Kansas City
	Research Medical Center
		Rakesh Gaur, MD	Ph:  913-948-5588
	Saint Luke's Cancer Institute at Saint Luke's Hospital
		Rakesh Gaur, MD	Ph:  913-948-5588
	Lee's Summit
	Saint Luke's East - Lee's Summit
		Rakesh Gaur, MD	Ph:  913-948-5588
	Saint Louis
	Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
		David Mutch, MD	Ph:  314-362-3181
	Springfield
	CCOP - Cancer Research for the Ozarks
		Robert Carolla	Ph:  417-269-4520
	Hulston Cancer Center at Cox Medical Center South
		Robert Carolla	Ph:  417-269-5257
	St. John's Regional Health Center
		Robert Carolla	Ph:  417-820-2000
Nebraska
	Omaha
	Methodist Estabrook Cancer Center
		Peter Morris, MD	Ph:  402-354-5250
Nevada
	Las Vegas
	Women's Cancer Center - La Canada
		Nick Spirtos, MD	Ph:  408-866-3843
	Reno
	Renown Institute for Cancer at Renown Regional Medical Center
		Peter Lim	Ph:  775-982-5050 866-559-0558
New Jersey
	Marlton
	Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
		Clinical Trials Office - Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton	Ph:  888-847-8823
	Morristown
	Carol G. Simon Cancer Center at Morristown Memorial Hospital
		Daniel Tobias	Ph:  973-971-6100 800-247-9580
	Neptune
	Jersey Shore Cancer Center at Jersey Shore University Medical Center
		Henry Sprance, MD, PhD	Ph:  732-776-4128
	New Brunswick
	Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
		Clinical Trials Office - Cancer Institute of New Jersey	Ph:  732-235-8675
	Phillipsburg
	Women’s Institute for Gynecologic Cancer and Special Pelvic Surgery
		David Silver, MD	Ph:  702-427-4999
	Voorhees
	Cancer Institute of New Jersey at Cooper - Voorhees
		Clinical Trials Office - Cancer Institute of New Jersey at Cooper University Hospital - Voorhees	Ph:  856-325-6757
New Mexico
	Albuquerque
	Southwest Gynecologic Oncology Associates, Incorporated
		Carolyn Muller, MD	Ph:  505-272-0185
	University of New Mexico Cancer Center
		Clinical Trials Office - University of New Mexico Cancer Center	Ph:  505-272-6972
	Las Cruces
	University of New Mexico Cancer Center - South
		Carolyn Muller, MD	Ph:  505-272-0185
New York
	Albany
	Women's Cancer Care Associates
		Thomas Morrissey	Ph:  518-458-1390
	Brooklyn
	SUNY Downstate Medical Center
		Ovadia Abulafia, MD	Ph:  718-270-2152
	Lake Success
	Monter Cancer Center of the North Shore-LIJ Health System
		Veena John	Ph:  516-734-8959
	Manhasset
	Don Monti Comprehensive Cancer Center at North Shore University Hospital
		Clinical Trials Office - Don Monti Comprehensive Cancer Center at North Shore University Hospital	Ph:  516-734-8900
	New Hyde Park
	Long Island Jewish Medical Center
		Veena John	Ph:  718-470-7000 800-371-7111
	New York
	Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
		Clinical Trials Office - Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center	Ph:  212-305-8615
	Memorial Sloan-Kettering Cancer Center
		Mario Leitao, Jr.	Ph:  212-639-8895 800-525-2225
	Mount Sinai Medical Center
		Jamal Rahaman	Ph:  212-241-6500
	NYU Cancer Institute at New York University Medical Center
		Stephanie Blank, MD	Ph:  212-263-2668
	Stony Brook
	Stony Brook University Cancer Center
		Clinical Trials Office - Stony Brook University Cancer Center	Ph:  800-862-2215
North Carolina
	Burlington
	Alamance Cancer Center at Alamance Regional Medical Center
		Janak Choksi, MD	Ph:  336-538-7737
	Chapel Hill
	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
		Clinical Trials Office - Lineberger Comprehensive Cancer Center	Ph:  877-668-0683; 919-966-4432
	Charlotte
	Blumenthal Cancer Center at Carolinas Medical Center
		Clinical Trials Office - Blumenthal Cancer Center at Carolinas Medical Center	Ph:  704-355-2884
	Presbyterian Cancer Center at Presbyterian Hospital
		Clinical Trials Office - Presbyterian Cancer Center at Presbyterian Hospital	Ph:  704-384-5369
	Durham
	Duke Cancer Institute
		Clinical Trials Office - Duke Cancer Institute	Ph:  888-275-3853
	Greensboro
	Moses Cone Regional Cancer Center at Wesley Long Community Hospital
		Clinical Trials Office - Moses Cone Regional Cancer Center at Wesley Long Community Hospital	Ph:  336-621-8374
	Raleigh
	Duke Health Raleigh Hospital
		Angeles Secord, MD	Ph:  919-684-3765
	Winston-Salem
	Wake Forest University Comprehensive Cancer Center
		Clinical Trials Office - Wake Forest University Comprehensive Cancer Center	Ph:  336-713-6771
Ohio
	Akron
	McDowell Cancer Center at Akron General Medical Center
		Eric Jenison, MD	Ph:  330-344-6041
	Summa Center for Cancer Care at Akron City Hospital
		Clinical Trials Office - Akron City Hospital	Ph:  330-375-6101
	Canton
	Aultman Cancer Center at Aultman Hospital
		Clinical Trials Office - Aultman Cancer Center at Aultman Hospital	Ph:  330-363-6891
	Cincinnati
	Charles M. Barrett Cancer Center at University Hospital
		William Richards	Ph:  806-796-1317
	Cleveland
	Case Comprehensive Cancer Center
		Clinical Trials Office - Case Comprehensive Cancer Center	Ph:  800-641-2422
	Cleveland Clinic Cancer Center at Fairview Hospital
		Clinical Trials Office - Cleveland Clinic Cancer Center at Fairview Hospital	Ph:  216-476-9362
	Cleveland Clinic Taussig Cancer Center
		Clinical Trials Office - Cleveland Clinic Taussig Cancer Center	Ph:  866-223-8100
	MetroHealth Cancer Care Center at MetroHealth Medical Center
		Peter Rose, MD	Ph:  216-444-1712
	Columbus
	Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
		Ohio State University Cancer Clinical Trial Matching Service	Ph:  866-627-7616
			Email: osu@emergingmed.com
	Riverside Methodist Hospital Cancer Care
		Clinical Trials Office - Riverside Methodist Hospital Cancer Care	Ph:  614-566-4475
	Dayton
	David L. Rike Cancer Center at Miami Valley Hospital
		Clinical Trials Office - David L. Rike Cancer Center at Miami Valley Hospital	Ph:  937-208-2079
	Kettering
	Charles F. Kettering Memorial Hospital
		Clinical Trials Office - Charles F. Kettering Memorial Hospital	Ph:  937-298-3399 ext. 57556
	Mayfield Heights
	Hillcrest Cancer Center at Hillcrest Hospital
		Peter Rose, MD	Ph:  216-444-1712
	Mentor
	Lake/University Ireland Cancer Center
		Steven Waggoner, MD	Ph:  216-844-5011
Oklahoma
	Oklahoma City
	Oklahoma University Cancer Institute
		Robert Mannel, MD	Ph:  405-271-8787
	Tulsa
	Cancer Care Associates - Saint Francis Campus
		Robert Mannel, MD	Ph:  405-271-8787
Oregon
	Portland
	Knight Cancer Institute at Oregon Health and Science University
		Clinical Trials Office - Knight Cancer Institute at Oregon Health and Science University	Ph:  503-494-1080
			Email: trials@ohsu.edu
	Northwest Cancer Specialists at Rose Quarter Cancer Center
		William Winter, III	Ph:  503-228-6509
Pennsylvania
	Abington
	Rosenfeld Cancer Center at Abington Memorial Hospital
		Clinical Trials Office - Rosenfeld Cancer Center at Abington Memorial Hospital	Ph:  215-481-2402
	Allentown
	Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
		Richard Boulay, MD	Ph:  610-402-3650
	Bethlehem
	St. Luke's Cancer Network at St. Luke's Hospital
		Nicholas Taylor	Ph:  610-954-3580
	Danville
	Geisinger Cancer Institute at Geisinger Health
		Clinical Trials Office - Geisinger Cancer Institute	Ph:  570-271-5251
	Hazleton
	Geisinger Hazleton Cancer Center
		James Bosscher	Ph:  570-459-2901
	Hershey
	Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
		Clinical Trials Office - Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center	Ph:  717-531-3779
			Email: CTO@hmc.psu.edu
	Philadelphia
	Abramson Cancer Center of the University of Pennsylvania
		Clinical Trials Office - Abramson Cancer Center of the University of Pennsylvania	Ph:  800-474-9892
	Fox Chase Cancer Center - Philadelphia
		Clinical Trials Office - Fox Chase Cancer Center - Philadelphia	Ph:  215-728-4790
	Fox Chase Cancer Center CCOP Research Base
		Clinical Trials Office - Fox Chase Cancer Center CCOP Research Base	Ph:  215-728-2983
	Joan Karnell Cancer Center at Pennsylvania Hospital
		Patricia Ford, MD	Ph:  215-829-6088
	Reading
	McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
		Clinical Trials Office - McGlinn Family Regional Cancer Center	Ph:  610-988-9323
	State College
	Geisinger Medical Group - Scenery Park
		James Bosscher	Ph:  814-231-4560
	Wilkes-Barre
	Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
		Clinical Trials Office - Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center	Ph:  570-271-5251
Rhode Island
	Providence
	Women and Infants Hospital of Rhode Island
		Clinical Trials Office - Women and Infants Hospital of Rhode Island	Ph:  401-274-1122
South Dakota
	Rapid City
	Black Hills Obstetrics & Gynecology LLP
		Helen Frederickson, MD	Ph:  605-343-9224
	Sioux Falls
	Avera Cancer Institute
		Luis Rojas-Espaillat	Ph:  605-322-3000
	Sanford Cancer Center at Sanford USD Medical Center
		Clinical Trials Office - Sanford Cancer Center	Ph:  605-328-1367
Texas
	Dallas
	Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
		Clinical Trials Office - Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas	Ph:  866-460-4673; 214-648-7097
	Fort Sam Houston
	Brooke Army Medical Center
		Clinical Trials Office - Brooke Army Medical Center	Ph:  210-916-4837
	Galveston
	University of Texas Medical Branch
		Clinical Trials Office - University of Texas Medical Branch	Ph:  409-772-1950
	Houston
	M. D. Anderson Cancer Center at University of Texas
		Clinical Trials Office - M. D. Anderson Cancer Center at the University of Texas	Ph:  713-792-3245
	Methodist Hospital
		Aparna Kamat	Ph:  713-441-1010
Utah
	Salt Lake City
	Huntsman Cancer Institute at University of Utah
		Clinical Trials Office - Huntsman Cancer Institute at University of Utah	Ph:  801-581-4477
			Email: clinical.trials@hci.utah.edu
Vermont
	Burlington
	Fletcher Allen Health Care - University Health Center Campus
		Clinical Trials Office - Fletcher Allen Health Care	Ph:  802-656-8990
Virginia
	Charlottesville
	University of Virginia Cancer Center
		Susan Modesitt	Ph:  434-924-9333 800-223-9173
	Richmond
	Virginia Commonwealth University Massey Cancer Center
		Clinical Trials Office -Virginia Commonwealth University Massey Cancer Center	Ph:  804-628-1939
Washington
	Bellingham
	PeaceHealth Medical Group, PC at St. Joseph Hospital
		Benjamin Greer, MD	Ph:  206-685-2463
	Bremerton
	Harrison Medical Center
		Benjamin Greer, MD	Ph:  206-685-2463
	Olympic Hematology and Oncology
		Benjamin Greer, MD	Ph:  206-685-2463
	Everett
	Providence Regional Cancer Partnership
		Benjamin Greer, MD	Ph:  206-685-2463
	Mount Vernon
	Skagit Valley Hospital Cancer Care Center
		Benjamin Greer, MD	Ph:  206-685-2463
	Poulsbo
	Harrison Poulsbo Hematology and Onocology
		Benjamin Greer, MD	Ph:  206-685-2463
	Seattle
	Fred Hutchinson Cancer Research Center
		Benjamin Greer, MD	Ph:  206-685-2463
	Group Health Central Hospital
		Clinical Trials Office - Group Health Central Hospital	Ph:  206-287-2900
	Northwest Hospital and Medical Center
		Benjamin Greer, MD	Ph:  206-685-2463
	Pacific Gynecology Specialists
		Benjamin Greer, MD	Ph:  206-685-2463
	Seattle Cancer Care Alliance
		Clinical Trials Office - Seattle Cancer Care Alliance	Ph:  800-804-8824
	Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
		Benjamin Greer, MD	Ph:  206-685-2463
	University Cancer Center at University of Washington Medical Center
		Benjamin Greer, MD	Ph:  206-685-2463
	Sequim
	Olympic Medical Cancer Center
		Benjamin Greer, MD	Ph:  206-685-2463
	Spokane
	Cancer Care Northwest - Spokane South
		Clinical Trials Office - Cancer Care Northwest - Spokane South	Ph:  509-228-1083
	Rockwood Clinic Cancer Treatment Center
		Clinical Trials Office - Rockwood Clinic Cancer Treatment Center	Ph:  509-838-2531 ext. 6880
	Tacoma
	Franciscan Cancer Center at St. Joseph Medical Center
		Clinical Trials Office - Franciscan Cancer Center	Ph:  253-426-6914
	MultiCare Regional Cancer Center at Tacoma General Hospital
		Clinical Trials Office - MultiCare Regional Cancer Center	Ph:  253-403-3229
	Walla Walla
	St. Mary Regional Cancer Center at St. Mary Medical Center
		Benjamin Greer, MD	Ph:  206-685-2463
	Wenatchee
	Wenatchee Valley Medical Center
		Clinical Trials Office - Wenatchee Valley Medical Center	Ph:  509-665-5800
Wisconsin
	Green Bay
	Green Bay Oncology, Limited at St. Mary's Hospital
		Jonathan Tammela	Ph:  920-884-3135
	Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
		Jonathan Tammela	Ph:  920-432-6049
	St. Vincent Hospital Regional Cancer Center
		Clinical Trials Office - St. Vincent Hospital Regional Cancer Center	Ph:  920-433-8889
	Madison
	University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
		Clinical Trials Office - University of Wisconsin Paul P. Carbone Comprehensive Cancer Center	Ph:  608-262-5223
	Marinette
	Bay Area Cancer Care Center at Bay Area Medical Center
		Jonathan Tammela	Ph:  715-735-6523 888-788-2070
	Milwaukee
	Aurora Sinai Medical Center
		Clinical Trials Office - Aurora Sinai Medical Center	Ph:  414-649-5717
	Medical College of Wisconsin Cancer Center
		Clinical Trials Office - Medical College of Wisconsin Cancer Center	Ph:  414-805-4380
	Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
		Clinical Trials Office - Vince Lombardi Cancer Clinic	Ph:  414-649-5717
	Sheboygan
	Vince Lombardi Cancer Clinic - Sheboygan
		Clinical Trials Office - Vince Lombardi Cancer Clinic - Sheboygan	Ph:  414-649-7200
	Two Rivers
	Vince Lombardi Cancer Clinic - Two Rivers
		Andrew Yetter	Ph:  920-793-6000
	Wausau
	University of Wisconcin Cancer Center at Aspirus Wausau Hospital
		Clinical Trials Office - University of Wisconsin Cancer Center	Ph:  608-262-5223
	West Allis
	Aurora Women's Pavilion of West Allis Memorial Hospital
		Peter Johnson, MD (Contact information may not be current)	Ph:  262-549-6662
Japan
	Hiroshima City
	Hiroshima University Hospital
		Hisaya Fujiwara	Ph:  81-82-261-3131
	Kagoshima City, Kagoshima
	Kagoshima City Hospital
		Masayuki Hatae, MD	Ph:  81-99-224-2101
	Kure
	National Hospital Organization - Medical Center of Kure
		Kazuhiro Takehara	Ph:  81-82-322-3111
	Minato-ku, Tokyo
	Jikei University School of Medicine Hospital
		Kyosuke Yamada	Ph:  81-3-3603-2111
	Niigata City
	Niigata University Medical and Dental Hospital
		Tetsuro Yahata
	Saitama
	Saitama Medical University International Medical Center
		Keiichi Fujiwara, MD, PhD	Ph:  81-42-984-4637
	Sapporo
	Hokkaido University Hospital
		Noriaki Sakuragi	Ph:  81-11-716-1161 ext. 6000
	Sendai
	Tohoku University Graduate School of Medicine
		Nobuo Yaegashi	Ph:  81-22-274-1111
	Tokyo
	National Cancer Center Hospital
		Mayu Yunokawa	Ph:  81-3-3542-2511
	Tottori
	Tottori University Hospital
		Junzo Kigawa, MD, PhD	Ph:  81-859-33-1111
Iwate
	Morioka
	Iwate Medical University Hospital
		Toru Sugiyama	Ph:  81-19-651-5111
Republic of Korea
	Goyang-si
	National Cancer Center - Korea
		Sang Park	Ph:  82-031-920-0001
	Jung-Ku
	Dongsan Medical Center of Keimyung University
		Chi-Heum Cho	Ph:  82-53-250-7114
	Seoul
	Asan Medical Center - University of Ulsan College of Medicine
		Young-Tak Kim	Ph:  82-2-224-3210
	Catholic University of Korea College of Medicine
		Jong-Sup Park	Ph:  82-2-593-5141
	Ewha Womans University Hospital
		Seung Kim	Ph:  82-2-760-5114
	Korea Cancer Center Hospital
		Moon-Hong Kim	Ph:  82-2-9702-114
	Samsung Medical Center
		Duk-Soo Bae	Ph:  82-2-3410-0200, 0220
	Seoul National University Hospital
		Soon-Beom Kang	Ph:  82-2-763-5110
	Suwon
	Ajou University Hospital
		Hee-Sug Ryu